C
352770
vs
K
KOSPI 200
Over the past 12 months, Clinomics Inc has underperformed KOSPI 200, delivering a return of 0% compared to the KOSPI 200's +123% growth.
Stocks Performance
352770 vs KOSPI 200
Performance Gap
352770 vs KOSPI 200
Performance By Year
352770 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Clinomics Inc
Glance View
Clinomics, Inc. conducts bio and medical research activities. The company is headquartered in Ulsan, Ulsan. The company went IPO on 2020-12-04. The firm's main businesses are multi-omics-based service business and liquid biopsy-based cancer diagnosis and screening business. The multi-omics-based service business provides products and services that predict physical characteristics and diseases based on genome diagnosis and tests, and provides early diagnosis services for major diseases such as cancer based on multi-omics. The liquid biopsy-based cancer diagnosis and screening business sells medical devices that diagnose patients by extracting blood cells and deoxyribonucleic acid (DNA), and diagnostic and monitoring kits for cancer mutations in patients. The company is also develops products that diagnoses cancer early with blood.
